Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks

Investigational New Drugs

Volumn 13, Issue 4, 1995, Pages 321-326

  Foster, Brenda J ^a   LoRusso, Patricia M ^a   Poplin, Elizabeth ^a   Zalupski, Mark ^a   Valdivieso, Manuel ^a   Wozniak, Antoinette ^a   Flaherty, Lawrence ^a   Kasunic, Dorothy A ^b   Earhart, Robert H ^b   Baker, Laurence H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

daily 5 Adozelesin Phase I

Indexed keywords

ADOZELESIN; CYTOTOXIC AGENT; MITOMYCIN C; NITROSOUREA; RACHELMYCIN;

ADULT; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG DNA BINDING; DRUG TOXICITY; DYSPNEA; FEMALE; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TOXICOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOHEXENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0029608618     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00873138     Document Type: Article

References (16)

1. Alkylating Agents
2. CC-1065 (NSC 298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism
3. Structure of CC-1065 (NSC 298223), a new antitumor antibiotic
4. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA
5. Mechanism of interaction of CC-1065 (NSC 298223) with DNA
6. Reactions of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity
7. Cell cycle effects of CC-1065
8. Preliminary toxicity studies with the DNA-binding antibiotic CC-1065
9. Stereoelectronic factors influencing the biological activity and DNA interactions of synthetic antitumor agents modeled on CC-1065
10. Adozelesin, a selected lead among cyclopropapyrroloindole analogs of the DNA-binding antibiotic, CC-1065
11. Toxicity and response criteria of the Eastern Cooperative Oncology Group
12. In vitro and in vivo bonding by the CC-1065 analogue U-73975
13. The duocarmycins: synthetic and mechanistic studies
14. Phase I study of adozelesin administered by 24 hour continuous intravenous infusion
15. Phase I study of adozelesin (U-73,975) in patients with solid tumors
16. Allergic reactions (AR) associated with cremophor (C) containing antineoplastics (ANP)